AngioDynamics, Inc. (ANGO) News
Filter ANGO News Items
ANGO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ANGO News Highlights
- For ANGO, its 30 day story count is now at 5.
- Over the past 14 days, the trend for ANGO's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
Latest ANGO News From Around the Web
Below are the latest news stories about ANGIODYNAMICS INC that investors may wish to consider to help them evaluate ANGO as an investment opportunity.
AngioDynamics to Present at the J.P. Morgan Healthcare ConferenceLATHAM, N.Y., December 21, 2023--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the J.P. Morgan 42nd Annual Healthcare Conference at 9:00 |
Why AngioDynamics (ANGO) Outpaced the Stock Market TodayThe latest trading day saw AngioDynamics (ANGO) settling at $7.63, representing a +1.87% change from its previous close. |
AngioDynamics (ANGO) Stock Drops Despite Market Gains: Important Facts to NoteAngioDynamics (ANGO) closed at $6.91 in the latest trading session, marking a -0.72% move from the prior day. |
AngioDynamics to Report Fiscal 2024 Second Quarter Financial Results on January 5, 2024LATHAM, N.Y., December 07, 2023--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that it will report financial results for the second quarter of fiscal year 2024 before the market open on Friday, January 5, 2024. The Company’s management will host a conference call at 8:00 a.m. ET the same |
AngioDynamics Completes Patient Enrollment in APEX-AV Study Assessing AlphaVac F1885 System in Treatment of Pulmonary EmbolismLATHAM, N.Y., December 07, 2023--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced the completion of patient enrollment in the Acute Pulmonary Embolism Extraction Trial with the AlphaVac System (APEX-AV). APEX-AV is a clinical study aimed at evaluating the safety and efficacy of the Company’s Alp |
AngioDynamics (ANGO) Falls More Steeply Than Broader Market: What Investors Need to KnowAngioDynamics (ANGO) closed the most recent trading day at $6.77, moving -1.31% from the previous trading session. |
CVRx (CVRX) Moves 7.1% Higher: Will This Strength Last?CVRx (CVRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. |
AngioDynamics (ANGO) Stock Slides as Market Rises: Facts to Know Before You TradeIn the most recent trading session, AngioDynamics (ANGO) closed at $6.74, indicating a -0.15% shift from the previous trading day. |
AngioDynamics (ANGO) Outperforms Broader Market: What You Need to KnowAngioDynamics (ANGO) closed the most recent trading day at $6.85, moving +1.33% from the previous trading session. |
AngioDynamics (ANGO) Advances But Underperforms Market: Key FactsIn the closing of the recent trading day, AngioDynamics (ANGO) stood at $6.21, denoting a +0.65% change from the preceding trading day. |